PLUVICTO

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, France, Ireland, Israel, Italy, Lithuania, Romania, UK.

Active ingredients

The drug PLUVICTO contains one active pharmaceutical ingredient (API):

1	Lutetium ¹⁷⁷Lu vipivotide tetraxetan UNII G6UF363ECX - LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
	Read more about Lutetium ¹⁷⁷Lu vipivotide tetraxetan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PLUVICTO Solution for injection/infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V10XX05		V Various → V10 Therapeutic radiopharmaceuticals → V10X Other therapeutic radiopharmaceuticals → V10XX Various therapeutic radiopharmaceuticals
Discover more medicines within V10XX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02530198
FR	Base de données publique des médicaments	68234294
IL	מִשְׂרַד הַבְּרִיאוּת	9237
IT	Agenzia del Farmaco	050419011
LT	Valstybinė vaistų kontrolės tarnyba	1096074
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69480001
US	FDA, National Drug Code	69488-010